中文名称: 兔抗RELB (Phospho-Ser573) 多克隆抗体
英文名称: Anti-RELB (Phospho-Ser573) rabbit polyclonal antibody
别 名: IREL; I-REL; REL-B
相关类别: 一抗
储 存: 冷冻(-20℃) 避光
宿 主: Rabbit
抗 原: RELB (Phospho-Ser573)
反应种属: Human Mouse Rat
标 记 物: Unconjugate
克隆类型: rabbit polyclonal
	 
						Background:
					 
						NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators.
					 
						Applications:
					 
						WB, IHC
					 
						Name of antibody:
					 
						RELB (Phospho-Ser573)
					 
						Immunogen:
					 
						Synthetic peptide of human RELB (Phospho-Ser573)
					 
						Full name:
					 
						v-rel reticuloendotheliosis viral oncogene homolog B (Phospho-Ser573)
					 
						Synonyms:
					 
						IREL; I-REL; REL-B
					 
						SwissProt:
					 
						Q01201
					 
						IHC positive control:
					 
						Human breast carcinoma
					 
						IHC Recommend dilution:
					 
						50-100
					 
						WB Recommended dilution:
					 
						500-1000
					 
						WB Positive control:
					 
						HUVEC cells untreated or treated with TNF
					 
						WB Predicted band size:
					 
						70 kDa
					
技术规格
	
		
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
			
					 
				
					 
			
				 
		
	
					 
				
					 
			

	
		

	
 购物车
购物车 帮助
帮助
 021-54845833/15800441009
021-54845833/15800441009 
              